ARMO BioSciences, Inc.

ARMO BioSciences, Inc., an immuno-oncology company, develops a pipeline of products that activate the immune system of cancer patients to recognize and eradicate tumors. Its products include AM0010, a long acting form of interleukin 10 (IL-10) that is an immune growth factor that naturally occurs in the body of humans and functions as a stimulator of the immune system; AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, a form of recombinant human interleukin-15 (IL-15); and AM0012, a form of recombinant human interleukin-12 (IL-12). ARMO BioSciences, Inc. was formerly known as Targenics, Inc. and changed its name to ARMO BioSciences, Inc. in December 2012. The company was incorporated in 2010 and is based in Redwood City, California. As of June 21, 2018, ARMO BioSciences, Inc. operates as a subsidiary of Eli Lilly and Company.